Advancing scientific knowledge
Explore the latest research from our scientists
Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma post CAR-T failure
Real-World characteristics and clinical outcomes in relapse/refractory diffuse large B-Cell lymphoma patients who received CAR-T therapy
Health-Related Quality of Life and Tolerability of Loncastuximab Tesirine in High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Camidanlumab tesirine: updated efficacy and safety in an open‐label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.
Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-cell non-Hodgkin lymphoma
Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy
Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma
CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors
A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia
Budget Impact Model for Loncastuximab Tesirine-Lpyl in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Real-time answers to your pressing questions
Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.Read and download our brochure
Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA. Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors
1The antibody drug conjugate (ADC) binds to a specific tumor cell surface antigen and is internalized1,2
2The potent pyrrolobenzodiazepine (PBD) dimer toxin is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix2,3
3Because these cross-links do not distort the DNA structure, it is hypothesized that they remain invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death1-3
Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)
A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumorsADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.Some of the agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.
Expand each compound to learn more.
Take a closer look at the LOTIS study designs
Explore the latest research from our scientists